Colossal generates value not by selling resurrected animals but by spinning out valuable technology companies developed during its R&D, such as a computational biology platform. The long-term vision involves biodiversity credits rather than direct sales.

The memo details how investors rationalize enormous funding rounds for pre-product startups. By focusing on a colossal potential outcome (e.g., a $1 trillion valuation) and assuming even a minuscule probability (e.g., 0.1%), the calculated expected value can justify the investment, compelling participation despite the overwhelming odds of failure.

To convince governments to protect ecosystems, Colossal Biosciences frames biodiversity not just as an environmental good, but as a source of economic value. Using the Gila monster's venom leading to the GLP-1 market as an example, they help nations underwrite and protect natural assets for their potential to create medical breakthroughs.

Anti-extinction startup Colossal is leveraging high-profile clients like Tom Brady for pet cloning. This creates buzz and revenue, effectively funding long-term R&D with a luxury consumer service while its more ambitious projects (reviving mammoths) are still in development.

Upcoming tech IPOs like SpaceX's are being valued on their compelling, aspirational narratives rather than traditional metrics like discounted cash flow (DCF). This suggests a market shift where investors store value in powerful, science-fiction-like stories over fundamentals.

CEOs of frontier model companies use grand, world-changing stories about AI's societal impact to justify raising tens of billions in capital. A modest narrative about a 'minor impact on compute' wouldn't secure the necessary funding, but this grandiosity later forces them into complex regulatory conversations.

Scientific founders must shift from detailing R&D progress to telling a compelling story. Investors are less moved by specific experimental results and more by the vision of a platform technology at the cusp of major trends (like SynBio and AI) that can generate a continuous pipeline of future therapies.

Perception and storytelling are overriding reality as the primary drivers of value. For investors, this means prioritizing companies with compelling, world-changing narratives (like SpaceX or OpenAI) over those that are simply 'fine businesses,' as the discontinuous upside comes from the power of the story.

xAI secured a $20B round, up from a rumored $15B, despite skepticism about its traction. The narrative shifted when possibilities of a merger into a larger "Elon Inc. Megacorp" with SpaceX emerged. This suggests that for certain high-profile founders, a grand, entertaining vision can trump conventional product metrics for investors.